LMG Life Sciences Awards EMEA 2024: key dates revealed
IFLR is part of the Delinian Group, Delinian Limited, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2023

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

LMG Life Sciences Awards EMEA 2024: key dates revealed

LMG Life Sciences Awards 2024 EMEA _ bkgrd_4x.png

Key dates for the LMG Life Sciences EMEA research for 2024 have been released

The LMG Life Sciences Awards EMEA is excited to announce its return for its fifth year and reveal its key dates for the 2024 research. The Awards will be open for submissions starting December 7.

Please note the following dates in your calendars:

Nominations Open

Nominations Close

Shortlist Published

Gala Ceremony

7 December 2023

25 January 2024

March 2024

May 2024

The life sciences industry will be invited to provide nominations for leading practitioners, firms, cases and deals. The Awards will recognise the most outstanding work completed by private practice law firms, as well as in-house legal teams and counsels during 2023.

If you have any questions about the research, please contact the LMG Life Sciences awards editor, John Harrison.

LMG Life Sciences produces the most respected awards programme for life sciences practitioners and law firms across Europe, the Middle East, and Africa. Honourees are determined through a rigorous research process that aims to recognise and celebrate excellent legal work and client service over a 12-month period.

The awards span four broad practice areas: regulatory, intellectual property, financial & corporate, and non-IP litigation & enforcement.

In addition to award categories for firms and individuals, an array of unique awards are announced each year to highlight the achievements of in-house teams and to celebrate Impact Cases and Deals of the Year.

Please note that LMG Life Sciences is a sister publication to and supported by IFLR but run independently to the IFLR1000 research.